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Objectives: Obesity is associated with an increased risk of breast cancer, and is 
also positively associated with tumor size and a higher probability of having posi-
tive axillary lymph nodes and faster growing tumors. It has been suggested that up 
to 50 % of postmenopausal breast cancers are attributable to obesity. Accordingly, 
this study assessed the impact of lifestyle intervention on body mass index (BMI) 
in women with breast cancer. MethOds: This is a randomized clinical trial study 
.The Study samples were 80 women with stage I, II, or III breast cancer, that oper-
ated for breast cancer and their chemotherapy or radiation therapy completed 3-18 
months ago. They are divided randomly into two groups; control group and lifestyle 
interventions group. Those in the lifestyle intervention group were instructed to 
practice aerobic exercises 45-60 minutes three times per week for 24 weeks with 
dietary energy restriction training. Those in the control group were instructed to 
continue normal activities and their routine health care. Data were obtained from 
the patient information form and body mass index form that completed before and 
after the lifestyle intervention in both groups. Results: No baseline differences 
existed between the two groups for the mean of BMI (p = 0.366) before the study 
; but the mean of BMI in the lifestyle intervention group after the intervention 
decreased to 25.12 ± 2.86, while in the control group it increased to 30.42 ± 6.89. The 
difference between the mean of BMI among the two groups after the intervention 
was statistically high (p = < 0.001). cOnclusiOns: Lifestyle intervention could be 
considered as part of a cancer survivorship program. For women with breast cancer, 
lifestyle intervention can decrease body mass index. Additional research in lifestyle 
intervention along with cognitive behavioral therapy also may be beneficial.
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Objectives: Minimally invasive hysterectomy using the Da Vinci robot-assisted 
surgical system remains uncertain if the technology offers benefits compared with 
traditional laparotomy. The aim of this study was to compare effectiveness and safety 
of robot-assisted laparoscopic hysterectomy (RALH) compared with traditional lapa-
rotomy in endometrial cancer. MethOds: We searched potentially relevant studies 
using Ovid-Medline, Ovid-EMBASE, Cochrane library, and 5 local medical databases 
through May 2014. The outcomes were overall complications, peri-operative complica-
tions, post-operative complications and specific morbidities for safety outcomes, sur-
vival, recurrence, length of stay (LOS), estimated blood loss (EBL), operative time (OT) 
for effectiveness outcomes. Two independent reviewers extracted data and assessed 
the risk of bias for non-randomized studies. Results: 19 eligible comparative studies 
representing 3,062 patients were identified. Overall and disease-free survival didn’t 
results in significant difference for 1 study. Pooled mean difference for resected total 
lymph nodes (LNs), pelvic LNs and aortic LNs showed no significant difference (WMD 
1.59, 95% CI -1.64-4.83, I2= 90%; WMD -1.64, 95% CI -4.21-0.94, I2= 91%; WMD 0.96, 95% 
CI -1.30-3.23, I2= 93%, respectively). LOS and OT was shorter for RALH (WMD -2.85, 
95% CI -3.28, -2.41, I2= 91%; WMD 44.15, 95% CI 20.91, 67.39, I2= 98%, respectively). 
EBL was significantly reduced in RALH group (WMD -159.62, 95% CI -189.73, -129.50, 
I2= 83%). Overall, intra-operative and post-operative complications (RR 0.37, 95% CI 
0.28-0.49, I2= 9%; RR 0.40, 95% CI 0.23-0.72, I2= 0%; RR 0.49, 95% CI 0.36-0.68, I2= 0%, 
respectively); the incidence of wound infection, wound dehiscence, wound com-
plications, ileus or bowel obstruction, infection, readmission, ICU stay, transfusion 
were significantly fewer but vaginal cuff dehiscence or separation were significantly 
higher in RALH than in laparotomy. Other individual peri-operative complications 
were similar. cOnclusiOns: RALH may be a generally safer and better option than 
laparotomy in endometrial cancer. Robotic surgery is associated with shorter LOS, 
OT; lower EBL and fewer complications than laparotomy. Further prospective studies 
with long term follow-up are required.
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Objectives: Patients with recurrent or metastatic SCCHN, particularly those with 
platinum-refractory disease, face limited treatment options that demonstrate dif-
ferentiated survival advantages and maintain or improve QoL. This study summa-
rized outcomes from systematically identified clinical studies reporting OS or QoL 
among patients with recurrent or metastatic SCCHN. MethOds: Eligible English-
language publications (01/2005–10/2014) were identified using EMBASE, MEDLINE, 
and the Cochrane Library. Results: Thirty-eight publications reporting clinical 
outcomes from 35 studies in all lines of therapy were identified (5902 patients). 
Most study arms received chemotherapy-based combinations. When stratified 
by prior treatment, median OS ranged from 7.4–11.1 months for platinum-naïve 
patients (11 arms), 4.3–11.8 months for platinum-refractory patients (12 arms), and 
5.0–32.2 months for patients with unspecified or mixed platinum history (38 arms). 
When stratified by current treatment regimen component, median OS ranged from 
4.3–12.4 months for cetuximab, 5.0–32.2 months for docetaxel, 5.2–6.7 months 
for methotrexate, and 4.3–19.1 months for paclitaxel. Among platinum-refractory 
patients, median OS ranged from 4.3–11.8 months for cetuximab, was 6.7 months 
for docetaxel and 5.2 months for methotrexate, and ranged from 4.3–11.7 months 
for paclitaxel. Fifteen studies reported QoL outcomes, including general-cancer 
and head-and-neck-specific QoL with impairments observed in domains includ-
ing eating, speech, appearance, and social impacts. Improvements, especially in 
pain, swallowing, and speech, were observed among platinum-naïve patients. 
However, among platinum-refractory patients, no statistically significant impacts 
on QoL were attributable to regimens including cetuximab or methotrexate, and 
no studies were identified reporting QoL outcomes with docetaxel or paclitaxel. 
line of treatment with a TKI (sunitinib, pazopanib, axitinib, or sorafenib) and/or 
mTOR inhibitor (everolimus or temsirolimus) during the study period (January 2012 
to February 2014) were identified by ICD9 code. Descriptive statistics were used to 
evaluate patterns of care in the overall sample. Univariate analysis was conducted to 
compare individual treatments. Multivariate analysis controlling for covariates will 
be shown in the poster. Results: 917 RCC patients meeting the study criteria were 
identified. Sunitinb (34%) was the most widely used drug followed by pazopanib 
(23%) and axitinib (14%). Mean duration of TKIs (3.7 mo) were higher than the mTOR 
(2.92) inhibitors (p= 0.004): sunitinib (3.87), pazopanib (3.67), axitinib (3.52), sorafenib 
(3.46), everolimus (3.12), and temsirolimus (2.58). Based on the univariate analysis 
there was statistically significant (p= 0.0054) but not clinically meaningful differ-
ence in duration across the individual treatments. cOnclusiOns: Real-world data 
analysis demonstrates significantly shorter duration of therapy of TKI and mTOR 
inhibitors than is published in clinical trials (range 4-8 months). Study results sug-
gest an unmet treatment need for RCC despite the rapid expansion of the number 
of drugs with an RCC indication in the past 5 years.
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Objectives: Approved treatment options for patients with recurrent GBM yield 
limited survival and QoL benefits. A systematic review was conducted to sum-
marize OS, QoL, and NF among patients with recurrent GBM. MethOds: Eligible 
English-language publications (01/2005–10/2014) were identified using EMBASE, 
MEDLINE, and the Cochrane Library. Results: Fifty publications were identified. 
Among bevacizumab-naïve patients treated with monotherapies, median OS ranged 
from 6.4–9.3 months with initial bevacizumab treatment, 6.6–9.4 months with other 
targeted therapies (enzastaurin, cediranib, and sunitinib), 7.1–11.7 months with 
chemotherapies (lomustine, verubulin, and temozolomide), and 10.9–11.4 months 
with the anti-hepatocyte growth factor monoclonal antibody rilotumumab. Among 
those treated with combination therapies, median OS ranged from 8.7–16.0 months 
with bevacizumab + chemotherapy, 5.6 months with bevacizumab + sorafenib, and 
9.4 months with cediranib + lomustine. Among patients with prior bevacizumab 
treatment, median OS was 3.4 months with verubulin, 4.4 months with sunitinib, 
and 3.4–3.6 months with rilotumumab. Among studies not specifically reporting 
outcomes for bevacizumab-naïve or -experienced patients, median OS ranged 
from 4.4 months with temsirolimus to 24.5 months with fotemustine. Factors that 
paralleled longer OS included male sex, younger age, fewer prior therapies, faster 
brain tissue diffusion on imaging, longer time to recurrence, smaller tumor volume, 
better performance status, and methylated O6-methylguanine-DNA methyltrans-
ferase promoter regions. Eight studies assessed the humanistic burden on patients. 
Baseline QoL and NF among these patients were worse compared with both the 
general population and patients with other cancers. No studies reported treatment-
related improvements in QoL or NF. cOnclusiOns: Currently available therapies 
for recurrent GBM are associated with limited OS duration and a lack of improve-
ments in QoL or NF. Among bevacizumab-naïve patients, initiation of bevacizumab 
or other mono- or combination therapies resulted in median OS less than 1.4 years, 
indicating a consistent unmet need in this population.
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COmPaRativE EffiCaCy Of imatiNib, dasatiNib aNd NilOtiNib fOR NEwly 
diagNOsEd CHRONiC myElOid lEukEmia iN CHRONiC PHasE (Cml-CP): a 
mEta-aNalysis aNd iNdiRECt COmPaRisON
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Objectives: Initial treatment of chronic myeloid leukemia in chronic phase (CML-CP) 
is very important and tyrosine kinase inhibitors (TKIs) are effective to delay the pro-
gression of chronic phase in accelerated and blastic phase. Dasatinib and nilotinib 
have been compared to imatinib as first line treatments for CML in two recent ran-
domised studies. However, no head to head evidence exists of the relative efficacy of 
dasatinib and nilotinib. The purpose of this study is to compare the clinical effects 
between the three targeted agents in CML patients. MethOds: We conducted a sys-
tematic review and used the data extracted to perform an indirect comparison meta-
analysis of the three interventions. A random-effects approach was used to estimate 
the probability of response at each time point, and indirect comparison was imple-
mented in the WinBUGS software packages. Results: Data from nine clinical studies 
(3 trials) were included. The risk ratio of complete cytogenetic response (CCyR) and 
major molecular response (MMR) for dasatinib and nilotinib were significantly better 
than imatinib (CCyR and MMR at 6 months: 1.24 to 1.49 and 2.75 to 3.35; CCyR and 
MMR at 12 months: 1.18 to 1.23 and 1.50 to 1.99). A result of comparing the three TKIs 
of CCyR or MMR at 12 and 24 months’ follow-up through Bayesian indirect comparison 
nilotinib is the treatment showed a better response than the dasatinib (dasatinib vs. 
nilotinib at 24 months CCyR (95%CrI): 0.798 (0.300-0.986) vs. 0.844 (0.382-0.990); dasat-
inib vs. nilotinib at 24 months MMR (95%CrI): 0.604 (0.112-0.955) vs. 0.683 (0.173-0.970)).
The overall survival and progression-free survival were not significantly different 
compared to the imatinib. cOnclusiOns: On the basis of a systematic review of 
the current literature base, dasatinib and nilotinib should be viewed as dominant 
compared to imatinib. However, further clinical studies directly comparing nilotinib 
and dasatinib are required for more accurate comparisons between the three TKIs.
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claims data to evaluate the relationship between dose modifications and persis-
tence among patients that receive 5 or more administrations. MethOds: Using 
data from the Cardinal Health Specialty Solutions Revenue Cycle Management 
medical claims database, 267 patients who received 5 or more eribulin adminis-
trations and completed therapy between May 2014 and April 2015 were included 
in the analyses. The Relative Dose Intensity (RDI) methodology compared the 
intensity of dose received per day of treatment against expected dose (recom-
mended dose) intensity. RDI values and total number of eribulin administrations 
were calculated for each patient based on the presence or absence of either dose 
reduction and/or dose delay. Data was analyzed using an independent samples 
t-test. Results: An analysis of patient distribution revealed the mean number of 
eribulin administrations was 13.4 with a mean RDI of 85%. Persistence was statisti-
cally higher in patients that had eribulin therapy managed through dose delay and 
dose reduction strategies. Patients with no modification (100% RDI) received an 
average of 8.1 eribulin administrations. Patients with dose modification (81% RDI) 
received an average of 14.5 eribulin administrations (p < 0.001). cOnclusiOns: 
Management of eribulin therapy in patients with MBC via dose delay and/or reduc-
tion resulted in a statistically significant increase in persistence among responding 
patients.
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a systEmatiC litERatuRE REviEw tO idENtify aNd COmPaRE CliNiCal 
tRials EvaluatiNg NOvEl tHERaPEutiC agENts iN POst-gEmCitabiNE 
advaNCEd PaNCREatiC CaNCER
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Objectives: There is currently no standard of care for patients with advanced 
pancreatic cancer (APC), including locally advanced and metastatic disease, 
who progressed following first-line therapy. Available treatment options have 
been limited by a lack of therapeutic breakthroughs, and primarily utilize dif-
ferent combinations and dosing schedules of established chemotherapeutic 
agents. The current review assesses the relative efficacy of new therapeutic 
agents tested, alone or in combination, since 2003 in patients with APC who 
progressed following gemcitabine-based therapy. MethOds: A systematic 
literature review was performed in PubMed/MEDLINE, EMBASE and ASCO 
meeting abstracts between January 2003 and June 2015. This review identi-
fied randomized controlled trials (RCTs) and single-arm trials evaluating new 
post-gemcitabine regimens in patients with APC. Results: A total of 34 trials, 
evaluating 1263 patients, were identified. New agents that have been tested 
include small molecules (24 trials), antibodies (3 trials), nanotherapeutics 
(4 trials), and immunotherapies (3 trials). The majority of studies were small, 
single-arm trials (n= 27). RCTs (n= 7, enrolling 835 patients) were further investi-
gated as they represent the standard for demonstrating therapeutic efficacy. At 
the time of analysis, the only Phase 3 RCT to evaluate a new therapeutic agent 
in post-gemcitabine APC was the NAPOLI-1 trial (nanoliposomal irinotecan 
(MM-398, nal-IRI) + 5-fluorouracil and leucovorin (5FU/LV) versus 5FU/LV), which 
was a large, global study that demonstrated a statistically significant improve-
ment in overall survival in patients with metastatic disease, including heavily-
pretreated patients. cOnclusiOns: The present review highlights the limited 
number of RCTs evaluating new therapeutic agents in patients with APC who 
previously received gemcitabine. Most new agents fail to be evaluated beyond 
small, uncontrolled trials of APC. Despite much research in this difficult-to-treat 
patient population with high unmet medical need, only one Phase 3 RCT of a 
new agent (nal-IRI) + 5FU/LV demonstrated significant improvement in overall 
survival in patients with APC who had progressed following gemcitabine-based 
therapy.
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Objectives: This study aimed to determine the demographic features, treat-
ment pattern, medication adherence, survival rates and associated healthcare 
costs in patients with newly diagnosed Ph+ CML from Korean National health 
Insurance (NHI) claims database MethOds: We conducted a longitudinal analy-
sis of patients with newly diagnosed Ph+ CML (ICD-10: C92.1) and started treat-
ment with imatinib in 2005 enrolled in the Korean NHI program. Patients were 
excluded if they had ≥ 1 claim with a diagnosis of other cancer within one year 
before diagnosis of CML. All data were retrieved from the NHI Database provided 
by National Health Insurance Corporation in Korea Results: In the study, a 
total of 8,986 patients with a diagnosis of Ph+ CML between January 1, 2004 and 
December 31, 2013 were identified. Among them, our study population consisted 
268 patients (mean age: 46.4±14.7 years, male: 57.4%) with the diagnosis of CML 
in 2005. The majority of patients (75.9%) initiated imatinib therapy at a starting 
dose was 400mg/day. With over 7 years of follow-up data, based on the 180-day 
gap definition of discontinuation, 33 (11.7%) patient was discontinued and discon-
tinuation period was 395.4±137.2 days (range: 189-1,023). Overall, 44.3% (n= 125) 
of patients were defined as Good Medication Possession Ratio (MPR) (≥ 90%) 
and 19.2% (n= 54) were as Poor MPR (< 70%). During follow-up period, 69 patients 
(24.5%) were deceased and the time to death for them was 3.18 years (1,159.5 ± 
845.1 days) after initiation of imatinib. Patients with Good MPR had significantly 
higher survival compared to patients with Poor MPR (p< 0.001). cOnclusiOns: 
In a retrospective assessment of a large cohort of patients with CP-CML treated 
with imatinib, we have shown that nonadherence to therapy is important factor 
for survival. Adherence to therapy must be included as an important evaluation 
parameter in all future studies of CML
Limited information was available linking disease severity to QoL. cOnclusiOns: 
In studies of patients receiving treatment for recurrent or metastatic SCCHN, 
median OS did not differ systematically among populations receiving regimens 
containing cetuximab, docetaxel, methotrexate, or paclitaxel. Among platinum-
refractory patients, no treatment was identified as having demonstrated signifi-
cant improvements in QoL.
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Objectives: The purpose of the current meta-analysis was to compare the effi-
cacy of lipegfilgrastim (LIP) to pegfilgrastim (PEG) and filgrastim (FIL). MethOds: 
EMBASE was searched for head-to-head trials examining the efficacy of LIP, PEG, or 
FIL. Outcomes included incidence of febrile neutropenia (FN), incidence of severe 
neutropenia (SN), duration of SN (DSN), and time to recovery of absolute neutrophil 
count (ANC). Direct comparisons of SN/FN between LIP and PEG were made using 
random-effects models estimating relative risk (RR). No trials directly compared 
LIP and FIL; indirect comparisons were made with PEG or placebo/no treatment 
(PLA) as the common comparator. For DSN/ANC recovery, generic inverse variance 
methods were employed. Results: Sixty-five studies were identified and 24 were 
included after full-text review and quality assessment via PRISMA criteria. Over all 
treatment cycles, LIP was non-inferior to PEG for risk of FN (RR 0.34, 95% CI: 0.05, 
2.14). The indirect estimate of FN for LIP versus FIL was also non-significant (RR 
0.22, 95% CI: 0.03, 1.51). For SN during cycle 1, LIP had a RR of 0.80 (95% CI: 0.63, 1.03) 
versus PEG and 0.79 (95% CI: 0.61, 1.03) versus FIL. For subsequent cycles, the RR 
was 0.53 (95% CI: 0.35, 0.79) LIP versus PEG and 0.45 (95% CI: 0.27, 0.75) versus FIL. 
Time to ANC recovery was significant: -1.75 days (95% CI: -2.61, -0.90) for LIP versus 
PEG and -1.88 days (95% CI: -2.82, -0.95) for LIP versus FIL. No comparions were 
significant for DSN. cOnclusiOns: LIP showed non-inferiority to PEG for risk of 
at least one FN episode and SN in cycle 1. LIP was more effective than both PEG and 
FIL for prevention of SN in cycles 2-4 and reduced ANC recovery time. However for 
DSN differences were not significant. These results suggest that LIP is a possibly 
more effective treatment.
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COmPaRativE EffECtivENEss Of gRaNulOCytE COlONy-stimulatiNg 
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Objectives: Effectiveness of daily G-CSF prophylaxis can be decreased when 
given in short courses. The objective was to determine the difference in odds of 
FN-related hospitalizations with once per cycle G-CSF (pegfilgrastim) prophylaxis 
compared to daily G-CSF (filgrastim/lenograstim) prophylaxis for patients receiving 
high/intermediate FN-risk chemotherapy for breast cancer or Non-Hodgkin lym-
phoma (NHL). MethOds: This retrospective cohort study used claims data from 
the Health Research Institute research database with < 4 million insured individuals 
in Germany. Patients receiving first-line, high/intermediate FN-risk chemotherapy 
for breast cancer or NHL from January 1, 2009 to December 31, 2013 were included 
and those cycles with G-CSF administration initiated ≤ 5 days following chemo-
therapy were assessed. G-CSF types were identified by ATC codes and FN-related 
hospitalizations within each cycle were identified by ICD-10-GM codes with a 
primary/secondary diagnosis of neutropenia (D70.1*, D70.7). Odds ratios (OR) for 
FN-related hospitalization and 95% confidence intervals (CI) were estimated with 
generalized estimating equation models and adjusted for age, gender, tumour type, 
metastatic status, cycle number, chemotherapy FN-risk and history of anaemia and 
surgery. Results: In total, 2,278 patients representing 7,918 cycles (6316 pegfil-
grastim, 1602 daily G-CSF) were included in the analysis; 2,037 (89%) patients had 
breast cancer and 241 (11%) had NHL. More than half of patients receiving pegfil-
grastim prophylaxis initiated it in cycle 1, primary prophylaxis, (56%) whereas 37% 
of patients receiving daily G-CSF prophylaxis initiated it in cycle 1. Three-quarters 
of patients receiving daily G-CSF were prescribed 5 or less doses in at least one 
cycle. Cycles with prophylactic daily G-CSF were associated with an increased 
risk of FN-related hospitalisations (adjusted OR= 2.19, 95% CI: 1.41-3.39; p-value 
< .001) in comparison to cycles with prophylactic pegfilgrastim. cOnclusiOns: 
This comparative effectiveness analysis showed a significantly higher likelihood 
of FN-related hospitalizations in cycles with daily G-CSF prophylaxis versus those 
with pegfilgrastim prophylaxis.
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Objectives: Eribulin mesylate is a microtubule inhibitor FDA approved for 
patients with MBC after treatment with at least two prior chemotherapeutic regi-
mens. The recommended dose of eribulin is 1.4 mg/m2 administered on Days 1 
and 8 of a 21-day cycle with options for dose modification (dose reduction/dose 
delay) based on severity and duration of specific toxicities. Recent studies, limited 
to the clinical trial setting, have shown dose modifications lead to greater treat-
ment persistence and improved patient outcomes. This study utilized real-world 
